



Press  
release

Montpellier, March 30<sup>th</sup> 2020 – 08h30 AM CEST

## World premiere availability of a new scanner visualization protocol dedicated to COVID-19

Intrasense (FR0011179886 - ALINS), a specialist in medical imaging software solutions and designer of Myrian, continues to support healthcare professionals within the current context. Following the availability for free of its clinical solutions useful for fighting the COVID-19 pandemic, the company announces the release and immediate availability of a specific scanner reading protocol dedicated to COVID-19.

### A new COVID-19 protocol based on Myrian XP-Lung

In the recent weeks, Intrasense teams worked with dedication to be able to provide medical teams with a new tool to fight the pandemic.

Following the recommendations issued by the major international professional medical societies, such as the [American College of Radiology](#) or the [Société Française de Radiologie](#), chest scanner is indicated as a reference exam for the follow-up of patients with a suspected or confirmed diagnosis and / or initial or secondary signs of clinical aggravation (dyspnea, desaturation, etc.).

According to these guidelines, the company has developed a specific reading protocol based on the pulmonary application XP-Lung of the Myrian platform. This protocol includes many clinical key points, particularly about screening, analysis of the pathological stages as well as clinical evolutions. The solution developed by Intrasense teams automatically and intuitively provides an objective measurement of the impairment and of the available pulmonary reserve of patients, allowing rapid identification of healthy and pathological areas (ground glass opacities, condensations, crazy paving, emphysematous areas). These elements provide the pulmonary reserve as well as a density histogram over a complete pulmonary volume.



## Immediate worldwide & free of charge deployment of the solution

Intrasense once again demonstrates its innovation capabilities and its strong responsiveness in supporting healthcare professionals through the current health crisis. This specific COVID-19 protocol, based on the pulmonary application Myrian XP-Lung, is offered free of charge to all healthcare

professionals fighting the COVID-19 pandemic, starting Monday, March 30<sup>th</sup>, 2020. It completes the offer of the company, already freely available within the context of the current crisis and enables radiologists to obtain a complete and unified clinical industrial solution. Access request to the solutions can simply be made by filling in the form available on the [company's website](#).

Intrasense teams are dedicated to best support the users of the solution and will continue in the coming weeks to improve its solutions based on the needs and feedback of healthcare professionals.

### About Intrasense

Founded in 2004, Intrasense develops and markets a unique medical device named Myrian®, a software platform facilitating and ensuring diagnosis, decision-making and therapeutic follow-up. Thanks to Myrian®, more than 1000 hospitals and clinics spread over 40 countries use a unique and integrated platform supporting all types of imaging modalities (MRI, scanner...). Enriched with expert clinical modules dedicated to specific pathologies and organs, Myrian® provides a universal medical image processing solution which can be fully integrated into any healthcare information system. Intrasense has more than 40 employees among which 15 are dedicated to Research & Development. Intrasense has been labelled 'innovative company' by the BPI and has invested more than 10 million euros in Research & Development since its creation. More information on: [www.intrasense.fr](http://www.intrasense.fr)

### Contacts

Intrasense  
Jérémy Peyron  
Marketing & Communication manager  
1231 avenue du Mondial 98, 34000  
Montpellier, FRANCE  
Tel: +334 67 130 130  
[investor@intrasense.fr](mailto:investor@intrasense.fr)

NewCap  
Investor Relations and Financial  
Communication  
Roxane Gbedigro  
Paris, FRANCE  
Tel: +331 44 71 20 43  
[intrasense@newcap.eu](mailto:intrasense@newcap.eu)

